Stereotaxis Wins FDA Clearance for Synchrony System Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures.

Stereotaxis Wins FDA Clearance for Synchrony System: Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures. 👈 Read full analysis #Stereotaxis #FDAClearance #SynchronySystem #CatheterAblation #STXS